+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
O

Actively Recruiting

Researchers are conducting a global Phase IV, open-label, randomized study to evaluate the safety and tolerability of acalabrutinib monotherapy compared to the investigators choice of treatment in adults with chronic lymphocytic leukemia CLL who also have moderate to severe heart problems. This study focuses on patients with significant cardiac impairment who might have been excluded from previous trials, aiming to better understand the safety profile of acalabrutinib in this specific group. The study involves collaboration between hematology and cardiology specialists, including cardio-oncologists. Participants will be randomly assigned to receive either acalabrutinib tablets taken orally twice daily or a treatment chosen by the investigator, which may include medications such as chlorambucil, venetoclax, or rituximab. Treatment cycles last 28 days, with initial frequent evaluations during the first eight cycles and less frequent assessments thereafter. Cardiology evaluations include consultations, echocardiograms, ECGs, Holter monitoring, and cardiac biomarker tests at specific intervals, with cardiac MRI performed yearly. Treatment continues until unacceptable side effects or disease progression. During the study, participants will have regular visits for blood tests, physical exams, and response assessments based on established criteria. Safety evaluations, especially for heart-related events, will be conducted throughout treatment and after discontinuation, with follow-up visits continuing until disease progression, withdrawal, death, or study end. Researchers will monitor cardiovascular adverse events leading to treatment changes, serious cardiac events, and overall survival, with follow-up lasting up to four years from the last participants enrollment.

Age: 18Years - 130YearsAll GendersPhase 4
23 locations